DARTRIX

DARPin Targeted Magnetic Hyperthermic Therapy for Glioblastoma

 Coordinatore UNIVERSITY COLLEGE LONDON 

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Mr.
Nome: Michael
Cognome: Browne
Email: send email
Telefono: +44 20 3108 9376
Fax: +44 20 3108 9376

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 7˙731˙609 €
 EC contributo 5˙998˙134 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2011-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-03-01   -   2017-02-28

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Mr.
Nome: Michael
Cognome: Browne
Email: send email
Telefono: +44 20 3108 9376
Fax: +44 20 3108 9376

UK (LONDON) coordinator 2˙557˙359.90
2    UNIVERSITAET ZUERICH

 Organization address address: Raemistrasse 71
city: ZURICH
postcode: 8006

contact info
Titolo: Prof.
Nome: Andreas
Cognome: Plückthun
Email: send email
Telefono: +41 44 635 55 70
Fax: +41 44 635 57 12

CH (ZURICH) participant 1˙086˙160.00
3    TOPASS GMBH

 Organization address address: DRAKESTRASSE 42
city: Berlin
postcode: 12205

contact info
Titolo: Prof.
Nome: Ulrich
Cognome: Pison
Email: send email
Telefono: +49 30 80907270
Fax: +49 30 80907266

DE (Berlin) participant 885˙397.00
4    RESONANT CIRCUITS LIMITED

 Organization address address: ALBERMALE STREET THE ROYAL 21
city: LONDON
postcode: W1S 4BS

contact info
Titolo: Mr.
Nome: Paul
Cognome: Southern
Email: send email
Telefono: +44 20 76 70 29 62

UK (LONDON) participant 611˙689.00
5    MICROMOD PARTIKELTECHNOLOGIE GMBH

 Organization address address: FRIEDRICH BARNEWITZ STRASSE 4
city: ROSTOCK
postcode: 18119

contact info
Titolo: Mr.
Nome: Fritz
Cognome: Westphal
Email: send email
Telefono: +49 381 54345 610
Fax: +49 381 54345 620

DE (ROSTOCK) participant 364˙900.00
6    ACIES Consulting Group SAS

 Organization address city: LYON
postcode: 69002

contact info
Titolo: Mr.
Nome: Vincent
Cognome: Grosbois
Email: send email
Telefono: +33 4 78924000
Fax: +33 4 78924001

FR (LYON) participant 267˙770.00
7    NANOPET PHARMA GMBH

 Organization address address: Robert-Koch-Platz 4
city: Berlin
postcode: 10115

contact info
Nome: Nicole
Cognome: Gärtner
Email: send email
Telefono: +49 30 890497414
Fax: +49 30 890497499

DE (Berlin) participant 224˙858.10
8    NOVAMEN SAS

 Organization address city: LYON
postcode: 69002

contact info
Titolo: Mr.
Nome: Vincent
Cognome: Grosbois
Email: send email
Telefono: +33 4 78924000
Fax: +33 4 78924001

FR (LYON) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

glioblastoma    die    protein    treatment    cells    tumour    dartrix    particles    diagnosis    mip    months    patients    scaffolds    gbm    exceptionally    ferucarbotran    particle    heat    generate    nanomag    affinity    gmp    cancer    magnetic    darpins   

 Obiettivo del progetto (Objective)

'DARTRIX, ‘DARPin Targeted RX (therapy)’ is a multidisciplinary collaborative project that will develop high-affinity protein scaffolds to create a new generation of targeted therapeutics for the treatment of glioblastoma. There is great need; glioblastoma is virtually incurable and most patients die within 12 months of diagnosis. DARPins are small, non-immunoglobulin human protein scaffolds that bind specific targets with exceptionally high-affinity. DARPins are amenable to GMP production and to scale-up. They are remarkably stable, even at high temperatures and they can be engineered to incorporate additional favourable properties to target glioblastoma cells with exceptionally high affinity. The new DARPins will be coupled to dextran-coated iron oxide nanoparticles, such as ferucarbotran or nanomag-MIP, which has been used clinically as a contrast agent for Magnetic Resonance Imaging (MRI). These ‘particles’ are safe to use in patients and are traceable within the body. When stimulated by an appropriate alternating magnetic current, the particles generate heat that can kill cancer cells very effectively. The conjugation of DARPins with ferucarbotran or nanomag-MIP (DARTRIX particle) leads to a potent therapeutic by delivering targeted hyperthermia to glioblastoma. In addition, DARTRIX particle will be created economically, exploiting the fact that DARPins can be produced to GMP in gram quantities using E. coli. The DARTRIX particles will target to glioblastoma cells by virtue of the high affinity and specificity of DARPins and the particles will remain in place when heated. By using DARPins to target the DARTRIX particle to tumour cells before application of the magnetic current, it should be possible to generate toxic heat specifically in the tumour. The consortium has all the skills and knowledge to develop DARPins from bench-to-bedside for glioblastoma treatment. This DARTRIX particle will pioneer targeted hyperthermic cancer treatment of glioblastoma in an innovative adaptive first-in-man trial, using direct injection or convection enhanced delivery to localise the particles to the tumour.'

Introduzione (Teaser)

Glioblastoma (GBM) is a rapidly progressive brain cancer and most patients die within 12 months of diagnosis. A radical new approach has to be applied for the development of GBM treatment.

Altri progetti dello stesso programma (FP7-HEALTH)

IMAGINT (2011)

HER Imaging and Molecular Interaction Mapping in Breast Cancer

Read More  

MITIGATE (2013)

Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with metastatic Gastrointestinal Stromal Tumours

Read More  

FLUINHIBIT (2008)

Small Molecule Inhibitors of the Trimeric Influenza Virus Polymerase Complex

Read More